Xeris Biopharma Holdings, Inc. (XERS)
NASDAQ: XERS · Real-Time Price · USD
7.36
0.00 (0.00%)
At close: Feb 2, 2026, 4:00 PM EST
7.22
-0.14 (-1.90%)
After-hours: Feb 2, 2026, 6:14 PM EST
Xeris Biopharma Holdings Employees
Xeris Biopharma Holdings had 394 employees as of December 31, 2024. The number of employees increased by 17 or 4.51% compared to the previous year.
Employees
394
Change (1Y)
17
Growth (1Y)
4.51%
Revenue / Employee
$675,475
Profits / Employee
-$39,695
Market Cap
1.22B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 394 | 17 | 4.51% |
| Dec 31, 2023 | 377 | 22 | 6.20% |
| Dec 31, 2022 | 355 | 61 | 20.75% |
| Dec 31, 2021 | 294 | 114 | 63.33% |
| Sep 30, 2021 | 325 | 153 | 88.95% |
| Jun 30, 2021 | 253 | 65 | 34.57% |
| Mar 31, 2021 | 209 | 10 | 5.03% |
| Dec 31, 2020 | 180 | -22 | -10.89% |
| Sep 30, 2020 | 172 | 38 | 28.36% |
| Jun 30, 2020 | 188 | 62 | 49.21% |
| Mar 31, 2020 | 199 | 109 | 121.11% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Immatics | 645 |
| Sana Biotechnology | 194 |
| Relay Therapeutics | 188 |
| Day One Biopharmaceuticals | 184 |
| Capricor Therapeutics | 160 |
| AnaptysBio | 136 |
| Inventiva | 84 |
| Taysha Gene Therapies | 73 |
XERS News
- 25 days ago - Xeris Expects to Deliver Record Fourth Quarter and Full-Year 2025 Total Revenue - Business Wire
- 4 weeks ago - Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Business Wire
- 2 months ago - Xeris Announces Notice of Allowance from U.S. Patent and Trademark Office for XP-8121 Patent Application - Business Wire
- 3 months ago - Xeris Biopharma Holdings, Inc. (XERS) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Xeris Biopharma Posts Record Financial Results for the Third Quarter 2025 - Business Wire
- 3 months ago - Xeris Biopharma to Report Third Quarter 2025 Financial Results on November 6, 2025 - Business Wire
- 4 months ago - Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 5 months ago - Xeris In Recorlev-Fuelled Growth: Why I Choose To Buy - Seeking Alpha